Get the Stockscreener App
8.98
2.81%
-0.26
After Hours:
9.05
0.07
+0.78%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $8.98, with a volume of 16.79M.
It is down -2.81% in the last 24 hours and down -16.85% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$9.24
Open:
$9.27
24h Volume:
16.79M
Relative Volume:
1.58
Market Cap:
$10.72B
Revenue:
$15.05B
Net Income/Loss:
$-883.30M
P/E Ratio:
-12.14
EPS:
-0.74
Net Cash Flow:
$1.89B
1W Performance:
-5.57%
1M Performance:
-16.85%
6M Performance:
-22.98%
1Y Performance:
-25.48%
1-Day Range:
$8.95
$9.36
1-Week Range:
$8.95
$9.735
52-Week Range:
$8.7701
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
8.98 | 10.72B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible - GlobeNewswire
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Viatris Inc. (VTRS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - PR Newswire
Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation | FinancialContent - Financial Content
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds - Investing.com
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds By Investing.com - Investing.com UK
Viatris Inc. (VTRS) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc.VTRS - PR Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Viatris Inc. (VTRS) Regarding Possible Securities Fraud Violations - ACCESS Newswire
ATTENTION Viatris Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Why Viatris Inc. (VTRS) Is Plunging So Far In 2025 - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Viatris Inc. (VTRS) And Encourages Investors to Connect - Markets Insider
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewswire
Viatris price target lowered to $13 from $15 at Jefferies - MSN
LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Jefferies cuts Viatris stock price target to $13, maintains Buy - Investing.com
Jefferies Adjusts Viatris Price Target to $13 From $15, Maintains Buy Rating -March 07, 2025 at 12:10 pm EST - Marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Viatris Inc. (VTRS) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Viatris Inc. (VTRS) and Encourages Investors to Learn More About the Investigation - Markets Insider
ATTENTION VTRS SHAREHOLDERS: Investors who lost money on Viatris Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Viatris to Present at the Barclays 27th Annual Global Healthcare Conference - PR Newswire
Viatris stock target cut to $10 by Piper Sandler, maintains neutral - Investing.com India
Forecasting The Future: 4 Analyst Projections For Viatris - Benzinga
Viatris price target lowered to $10 from $14 at Piper Sandler - TipRanks
Viatris Inc. Being Investigated on Behalf of Viatris Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Piper Sandler Adjusts Price Target on Viatris to $10 From $14, Maintains Neutral Rating - Marketscreener.com
Analyst recommendations: Applovin, Palantir, T-Mobile US, Constellation Brands, Viatris… - Marketscreener.com
Wall Street Wary as Viatris (VTRS) Dives into Generic Weight Loss Drug Market - Markets Insider
Viatris outlines $450M-$550M product revenue target for 2025 while addressing Indore impact - MSN
Viatris: A Unique S&P 500 'Fallen Angel' With Intriguing Potential (NASDAQ:VTRS) - Seeking Alpha
Lidocaine Patches Market Set to Witness Significant Growth by 2025-2032:Endo International plc, Viatris Inc, - EIN News
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris ‘Actively Launching’ Glucagon As It Looks To Deliver On Pipeline Promise - News & Insights
Viatris Inc. rating downgraded by S&P due to high leverage expectations - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Encourages Viatris Inc. (VTRS) Investors to Inquire about Securities Investigation - Markets Insider
Is Viatris Inc. (VTRS) the Best Weight Loss Drug Stock to Buy According to Analysts? - Insider Monkey
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris - GlobeNewswire
Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings - Nasdaq
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Stock Of The Day: Why The Viatris Meltdown Ended Where It Did - Benzinga
Lost Money on Viatris Inc. (VTRS)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Investors to Reach Out - Markets Insider
Barclays Adjusts Price Target on Viatris to $9 From $12, Keeps Underweight Rating - Marketscreener.com
Viatris Inc. stock falls Thursday, underperforms market - MSN
Why Viatris Inc. (VTRS) Went Down on Thursday - MSN
Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025 - News & Insights
Viatris Inc. (NASDAQ:VTRS) Q4 2024 Earnings Call Transcript - Insider Monkey
Viatris Inc.: A Comprehensive Analysis of Financial Performance, Strategic Initiatives, and Market Challenges - HPBL
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):